KR20220140647A - 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 - Google Patents

과다운동성 운동 장애의 치료를 위한 vmat2 억제제 Download PDF

Info

Publication number
KR20220140647A
KR20220140647A KR1020227034399A KR20227034399A KR20220140647A KR 20220140647 A KR20220140647 A KR 20220140647A KR 1020227034399 A KR1020227034399 A KR 1020227034399A KR 20227034399 A KR20227034399 A KR 20227034399A KR 20220140647 A KR20220140647 A KR 20220140647A
Authority
KR
South Korea
Prior art keywords
htbz
dimethoxy
isobutyl
pyrido
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227034399A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 에프. 오브라이언
Original Assignee
뉴로크린 바이오사이언시즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로크린 바이오사이언시즈 인코퍼레이티드 filed Critical 뉴로크린 바이오사이언시즈 인코퍼레이티드
Priority to KR1020247001490A priority Critical patent/KR20240011255A/ko
Publication of KR20220140647A publication Critical patent/KR20220140647A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227034399A 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 Ceased KR20220140647A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247001490A KR20240011255A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
KR1020207032879A KR20200133003A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207032879A Division KR20200133003A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001490A Division KR20240011255A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Publications (1)

Publication Number Publication Date
KR20220140647A true KR20220140647A (ko) 2022-10-18

Family

ID=53264772

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020227034399A Ceased KR20220140647A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020257005033A Pending KR20250029267A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020247001490A Ceased KR20240011255A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020207032879A Ceased KR20200133003A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020167033765A Ceased KR20160147044A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020257005033A Pending KR20250029267A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020247001490A Ceased KR20240011255A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020207032879A Ceased KR20200133003A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020167033765A Ceased KR20160147044A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Country Status (24)

Country Link
US (3) US20170071932A1 (cg-RX-API-DMAC7.html)
EP (3) EP4389227A3 (cg-RX-API-DMAC7.html)
JP (4) JP6635945B2 (cg-RX-API-DMAC7.html)
KR (5) KR20220140647A (cg-RX-API-DMAC7.html)
CN (3) CN112741836A (cg-RX-API-DMAC7.html)
AU (1) AU2015256012B2 (cg-RX-API-DMAC7.html)
CA (1) CA2947736C (cg-RX-API-DMAC7.html)
CY (1) CY1125058T1 (cg-RX-API-DMAC7.html)
DK (2) DK3936130T3 (cg-RX-API-DMAC7.html)
ES (2) ES2976207T3 (cg-RX-API-DMAC7.html)
FI (1) FI3936130T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20240459T1 (cg-RX-API-DMAC7.html)
HU (2) HUE057839T2 (cg-RX-API-DMAC7.html)
IL (1) IL248745B (cg-RX-API-DMAC7.html)
LT (2) LT3139925T (cg-RX-API-DMAC7.html)
MX (1) MX387625B (cg-RX-API-DMAC7.html)
NZ (1) NZ725826A (cg-RX-API-DMAC7.html)
PL (2) PL3936130T3 (cg-RX-API-DMAC7.html)
PT (2) PT3936130T (cg-RX-API-DMAC7.html)
RS (2) RS65359B1 (cg-RX-API-DMAC7.html)
RU (1) RU2753740C2 (cg-RX-API-DMAC7.html)
SI (2) SI3936130T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202400199T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015171802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7109360B2 (ja) 2015-10-30 2022-07-29 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジン塩およびその多形体
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
CN109153676B (zh) * 2016-06-29 2021-08-10 苏州科睿思制药有限公司 Nbi-98854的晶型及其制备方法和用途
JP2020500875A (ja) * 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
EA201991782A1 (ru) 2017-01-27 2021-09-23 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2022104034A (ru) * 2017-04-01 2022-03-05 Адептио Фармасьютикалз Лимитед Фармацевтические композиции
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2771164C2 (ru) * 2017-04-01 2022-04-27 Адептио Фармасьютикалз Лимитед (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CN111372567B (zh) 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2019074492A1 (en) * 2017-10-10 2019-04-18 Obrien Christopher F METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
US11306082B2 (en) * 2017-11-08 2022-04-19 Foresee Pharmaceuticals Co., Ltd. Esters of dihydrotetrabenazine
WO2019129100A1 (zh) 2017-12-26 2019-07-04 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
US12144899B2 (en) * 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
IL320987A (en) 2018-08-15 2025-07-01 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
EP3965764A1 (en) * 2019-05-09 2022-03-16 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2081929E (pt) * 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
NO3061760T3 (cg-RX-API-DMAC7.html) 2008-09-18 2018-04-07
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
NZ705372A (en) 2012-09-18 2018-07-27 Auspex Pharmaceuticals Inc Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2021128797A (ru) * 2014-02-07 2021-11-26 Ньюрокрайн Байосайенсиз, Инк. Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение

Also Published As

Publication number Publication date
CY1125058T1 (el) 2023-06-09
CN106456629A (zh) 2017-02-22
MX387625B (es) 2025-03-18
US20210196702A1 (en) 2021-07-01
NZ725826A (en) 2023-05-26
US20200101063A1 (en) 2020-04-02
KR20160147044A (ko) 2016-12-21
EP3936130A1 (en) 2022-01-12
RU2016147523A3 (cg-RX-API-DMAC7.html) 2018-12-28
US20170071932A1 (en) 2017-03-16
IL248745B (en) 2022-07-01
HRP20220025T1 (hr) 2022-04-01
RS65359B1 (sr) 2024-04-30
KR20250029267A (ko) 2025-03-04
AU2015256012B2 (en) 2020-07-23
IL248745A0 (en) 2017-01-31
RU2016147523A (ru) 2018-06-08
JP2024153782A (ja) 2024-10-29
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
LT3139925T (lt) 2022-01-25
EP4389227A2 (en) 2024-06-26
PT3139925T (pt) 2022-01-26
CA2947736A1 (en) 2015-11-12
SMT202200193T1 (it) 2022-07-21
DK3139925T3 (da) 2021-12-20
SMT202400199T1 (it) 2024-07-09
EP3139925B1 (en) 2021-12-01
SI3936130T1 (sl) 2024-05-31
RS62782B1 (sr) 2022-01-31
PT3936130T (pt) 2024-04-17
KR20200133003A (ko) 2020-11-25
EP3936130B1 (en) 2024-02-14
RU2753740C2 (ru) 2021-08-23
JP2021191799A (ja) 2021-12-16
CN112741836A (zh) 2021-05-04
WO2015171802A1 (en) 2015-11-12
JP2017514850A (ja) 2017-06-08
JP6635945B2 (ja) 2020-01-29
PL3139925T3 (pl) 2022-03-21
JP2019218407A (ja) 2019-12-26
EP3139925A1 (en) 2017-03-15
KR20240011255A (ko) 2024-01-25
CA2947736C (en) 2023-04-18
HUE066361T2 (hu) 2024-07-28
MX2016014429A (es) 2017-04-06
SI3139925T1 (sl) 2022-04-29
HUE057839T2 (hu) 2022-06-28
EP4389227A3 (en) 2024-09-04
ES2976207T3 (es) 2024-07-26
DK3936130T3 (da) 2024-03-25
LT3936130T (lt) 2024-04-25
CN112741835A (zh) 2021-05-04
HRP20240459T1 (hr) 2024-06-21
FI3936130T3 (fi) 2024-04-23
PL3936130T3 (pl) 2024-06-10

Similar Documents

Publication Publication Date Title
US20210196702A1 (en) Treatment of hyperkinetic movement disorders
US20080255079A1 (en) Therapeutic Use of Nefopam and Analogues Thereof
US20230355618A1 (en) Raf inhibitor for treating low grade glioma
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
JP2025087929A (ja) うつ病および／またはうつ状態の治療および／または予防用医薬
CN117615757A (zh) 用于治疗抑郁症的组合物和方法
EP2255807A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem
US20080070952A1 (en) Inhibition or Treatment of Dyskinesia
TW201345528A (zh) 用於組合療法之醫藥組合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221004

Application number text: 1020207032879

Filing date: 20201113

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221102

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230207

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230814

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230207

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240115

Application number text: 1020207032879

Filing date: 20201113